Not taking enough vitamin D can cause more harm than you’ve heard. Take the risk to heart health, for example. But no worries ...

A pig kidney with one genetic change functioned in a brain-dead human for 61 days, more than doubling previous records.

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the ...

A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

Cancer treatments can exert cardiotoxic effects, but screening and monitoring can detect and minimize cancer therapy-related ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with ...

Given the success of atacicept in phase 2 trials, investigators tested the dual inhibitor of BAFF and APRIL in patients with IgA nephropathy in the phase 3 ORIGIN trial.

H OUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients ...

The results of high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced ...

C3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients V-INCEPTION analyses highlight ...